Los Angeles Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Los Angeles Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.11M	Buy	49,934 +138	+0.3%	+$3.3K	﹤0.01%	648
2025 Q4	$1.13M	Sell	49,796 -14,152	-22%	-$338K	﹤0.01%	586
2025 Q3	$1.36M	Sell	63,948 -1,209	-2%	-$28.6K	﹤0.01%	611
2025 Q2	$1.41M	Sell	65,157 -76,900	-54%	-$1.43M	0.01%	548
2025 Q1	$2.36M	Buy	142,057 +27,522	+24%	+$500K	0.01%	375
2024 Q4	$2.1M	Buy	114,535 +70,238	+159%	+$1.13M	0.01%	441
2024 Q3	$681K	Sell	44,297 -6,672	-13%	-$111K	﹤0.01%	776
2024 Q2	$828K	Sell	50,969 -16,505	-24%	-$266K	﹤0.01%	719
2024 Q1	$1.25M	Buy	67,474 +2,295	+4%	+$56.9K	﹤0.01%	622
2023 Q4	$2.04M	Buy	65,179 +19,871	+44%	+$475K	0.01%	479
2023 Q3	$944K	Buy	45,308 +3,771	+9%	+$102K	﹤0.01%	660
2023 Q2	$995K	Buy	41,537 +16,093	+63%	+$358K	﹤0.01%	656
2023 Q1	$479K	Buy	+25,444	New	+$485K	﹤0.01%	863
2021 Q2	–	Sell	-16,458	Closed	-$425K	–	1519
2021 Q1	$425K	Sell	16,458 -24,580	-60%	-$1.08M	﹤0.01%	1286
2020 Q4	$2.19M	Sell	41,038 -5,025	-11%	-$249K	0.01%	626
2020 Q3	$1.9M	Sell	46,063 -31,641	-41%	-$1.37M	0.01%	586
2020 Q2	$3.77M	Buy	77,704 +12,374	+19%	+$594K	0.02%	458
2020 Q1	$2.76M	Buy	65,330 +20,297	+45%	+$836K	0.02%	461
2019 Q4	$1.93M	Buy	45,033 +3,574	+9%	+$155K	0.01%	652
2019 Q3	$1.49M	Buy	41,459 +25,739	+164%	+$780K	0.01%	706
2019 Q2	$420K	Sell	15,720 -17,325	-52%	-$443K	﹤0.01%	1096
2019 Q1	$887K	Buy	+33,045	New	+$772K	﹤0.01%	893
2018 Q3	–	Sell	-450,345	Closed	-$6.88M	–	1378
2018 Q2	$6.88M	Buy	+450,345	New	+$8.03M	0.04%	427
2015 Q2	–	Sell	-12,775	Closed	-$416K	–	1200
2015 Q1	$416K	Buy	+12,775	New	+$439K	﹤0.01%	974

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Los Angeles Capital Management's ACAD Position: Q1 2026 in Review

Los Angeles Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 0.28% in Q1 2026, buying an estimated $3.3K and bringing the position to 49,934 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #648.

Los Angeles Capital Management first reported a position in ACAD in Q1 2015 and has held it in 24 quarters since. The position peaked at $6.88M in Q2 2018. 342 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Los Angeles Capital Management held 49,934 shares of Acadia Pharmaceuticals worth $1.11M as of Q1 2026.
Los Angeles Capital Management bought 138 Acadia Pharmaceuticals shares in Q1 2026, an estimated $3.3K.
Acadia Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #648 holding.
Los Angeles Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2015 and has held it in 24 quarters since.
Los Angeles Capital Management's Acadia Pharmaceuticals position peaked at $6.88M in Q2 2018.
342 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.